Catalyst Event
Alnylam Pharmaceuticals Inc (ALNY) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
5/12/2026, 12:00:00 AM
Alnylam presented new positive analyses from the HELIOS-B Phase 3 study of vutrisiran at the Heart Failure 2026 conference (May 9-12), showing consistent clinical benefits for patients with ATTR-CM.
Korean Translation
Heart Failure 2026 학회(5월 9-12일)에서 ATTR-CM 환자에 대한 일관된 임상적 이점을 보여주는 vutrisiran의 HELIOS-B 3상 연구에 대한 새로운 긍정적 분석 결과 발표함.
Related Recent Events
ON Semiconductor Corp (ON) · Other
Financial Analyst Day 2026 is scheduled for 2026-09-16; this event is estimated to have a ≥1% price impact, scheduled.
9/16/2026, 12:00:00 AM
Roblox Corp (RBLX) · Earnings Release
Roblox is scheduled to release its Q2 2026 earnings report on 2026-08-11. Low importance is estimated as date announcements have minimal impact, scheduled
8/11/2026, 12:00:00 AM
Kratos Defense & Security Solutions Inc (KTOS) · Earnings Release
Next quarterly earnings report for Q2 2026 is scheduled. Market impact is estimated at Medium as earnings releases typically result in 5-10% price movement.
8/6/2026, 12:00:00 AM
Curtiss-Wright Corp (CW) · Earnings Release
Q2 2026 earnings release expected.
8/5/2026, 12:00:00 AM
Occidental Petroleum Corp (OXY) · Earnings Release
Occidental Petroleum is expected to report its Q2 2026 earnings results around August 5, 2026, based on historical patterns expected.
8/5/2026, 12:00:00 AM
Masco Corporation (MAS) · Earnings Release
Masco's Q2 2026 earnings release is scheduled for July 30, 2026. Estimated 5% impact based on historical volatility during earnings periods expected.
7/30/2026, 12:00:00 AM